Home › Funds › ACUTA CAPITAL PARTNERS, LLC › ANTX
ACUTA CAPITAL PARTNERS, LLC position in ANTX
AN2 THERAPEUTICS INC · Health Care
ACUTA CAPITAL PARTNERS, LLC reported holding 142,051 shares of ANTX (AN2 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$756K, representing 0.60% of its reported portfolio and ranking #29 among its reported holdings. ACUTA CAPITAL PARTNERS, LLC has disclosed ANTX holdings in 3 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ACUTA CAPITAL PARTNERS, LLC's ANTX position evolved
ACUTA CAPITAL PARTNERS, LLC first disclosed a stake in ANTX in Q3 2023 at 13,300 shares (US$214K). The position peaked in Q4 2023 at 132,000 shares, worth US$2.7M. Across 3 filings, ACUTA CAPITAL PARTNERS, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 142,051 shares valued at US$756K. Notable position changes include a 892% increase in Q4 2023 (shares fell 84% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 13.30K | $213.86K | New |
| Q4 2023 | 132.00K | $2.70M | Add |
| Q3 2026 | 142.05K | $755.71K | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANTX and 13F data
ANTX (AN2 THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in ANTX — the largest reported positions include Vivo Capital, LLC (US$16.8M), Commodore Capital LP (US$14.2M), Spruce Street Capital LP (US$9.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANTX
- Vivo Capital, LLC 3.15M sh · $16.78M · Q3 2026
- Commodore Capital LP 2.93M sh · $14.20M · Q2 2026
- Spruce Street Capital LP 1.75M sh · $9.32M · Q3 2026
- Almitas Capital LLC 1.47M sh · $7.11M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.30M sh · $6.92M · Q3 2026
- Boxer Capital Management, LLC 749.03K sh · $3.63M · Q2 2026
- Tetragon Partners GP Ltd 603.42K sh · $3.21M · Q3 2026
- Sio Capital Management, LLC 548.10K sh · $2.92M · Q3 2026
- Ally Bridge Group (NY) LLC 526.32K sh · $2.55M · Q2 2026
- Aldebaran Capital, LLC 367.71K sh · $1.96M · Q3 2026
- Prosight Management, LP 350.88K sh · $1.87M · Q3 2026
- Stonepine Capital Management, LLC 350.88K sh · $1.87M · Q3 2026
More on ACUTA CAPITAL PARTNERS, LLC
FAQ
How long has ACUTA CAPITAL PARTNERS, LLC held ANTX?
ACUTA CAPITAL PARTNERS, LLC has disclosed ANTX holdings in 3 of the last 13 reported quarters, going back to Q3 2023.
What is ACUTA CAPITAL PARTNERS, LLC's current position in ANTX?
As of Q3 2026, ACUTA CAPITAL PARTNERS, LLC holds 142.05K shares of ANTX (AN2 THERAPEUTICS INC), valued at $755.71K, representing 0.60% of its reported portfolio and ranking #29.
Has ACUTA CAPITAL PARTNERS, LLC been buying or selling ANTX?
In the latest 13F filing (Q3 2026), ACUTA CAPITAL PARTNERS, LLC newly opened its position in ANTX. The position peaked in Q4 2023 at 132.00K shares.
Which other funds hold ANTX?
Other major institutional holders of ANTX include Vivo Capital, LLC, Commodore Capital LP, Spruce Street Capital LP, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.